triple-negative breast cancer – Discover Pharma

Welcome to Discover Pharma! Today is : October 30, 2026

triple-negative breast cancer

Drug Discovery & Development,Research & Development
Ryvu reports preclinical results for novel ADC payload
Ryvu Therapeutics has reported preclinical results for RVU602, an experimental [...]

October 19, 2026
Clinical & Regulatory,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas
Kazia reports 83% response rate for paxalisib in triple-negative breast cancer
Early Phase 1b data show five objective responses among six [...]

September 14, 2026
Drug Delivery & Formulation,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas
Cancer vaccine research secures $2.5M NIH award for nanoparticle treatment
A $2.5m National Institutes of Health award will support research [...]

September 14, 2026
Advanced Therapies,Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development,Therapeutic Areas
Inaphaea BioLabs boosts precision oncology with new partnerships, advanced tumour models, and digital patient avatars
Inaphaea BioLabs, the translational contract research organisation (CRO) of ValiRx [...]

May 5, 2026

This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details.

OK